Kangzhi Pharmaceutical Co., Ltd. is a listed company focusing on children's health (stock abbreviation: Kangzhi Pharmaceutical, stock code: 300086). The main business covers children's medicine, maternal and infant health products, medical services and other fields. It is a national high-tech enterprise and has established a postdoctoral research station with children's medicine as its main research direction. The company adheres to the corporate purpose of "being sincere and good at doing medicine and benefiting mankind", actively implements the "children's big health strategy" and "quality strategy", and ingeniously creates a national brand of the children's big health industry.

Kangzhi Pharmaceutical has been deeply engaged in the children's drug market for many years and has formed a complete product line. It is one of the few pharmaceutical companies in China that have the entire industrial chain of children's drug research and development, production and sales. The company's territory is nationwide, with five major production bases in Hainan, Beijing, Hebei, Liaoning and Guangdong provinces and cities, and highly automated and intelligent production lines. The company has advanced R&D equipment and excellent R&D team.

In 2018, Kangzhi Pharmaceutical acquired Zhongshan Aihu Daily necessities Co., Ltd., and its business layout extended to the maternal and infant health sector. Kangzhi Children's Big Health Map is becoming more and more perfect. Aihu Company has successively established cooperation with many domestic and foreign scientific research institutions and universities, and has been invited to participate in the formulation of the "Liquid Detergent for Infant and Children's Clothing Materials" standards. It is a benchmark enterprise in the field of maternal and infant health in China.

At the beginning of 2020, the new crown pneumonia epidemic swept the world. Kangzhi Pharmaceutical was ordered to volunteer to produce masks and other protective materials in an emergency. It built Hainan's first disposable medical mask production line in just 8 days, and successfully obtained ENISO13485:2016 EU Quality Management System Certification , and in September 2020, he became a manufacturer of anti-epidemic mask materials for the United Nations Development Program.